Northwestern University recently completed an observational study reviewing data from 132,737 patients with type 2 diabetes who were initiating second-line treatment. The investigators concluded that common type 2 diabetes medications including sulfonylureas and basal insulin put patients at greater risk for cardiovascular harm. The Times Now News article reports that newer diabetes drugs, although more expensive, are safer as second-line treatment after metformin.  They include the following:

    • GLP-1 agonists (e.g. liraglutide)
    • SGLT-2 inhibitors (e.g. empagliflozin)
    • DPP-4 inhibitors (e.g. sitagliptin)

Lead Research/Investigator

Dr. Matthew O’Brien

Source: Times Now News

Pin It on Pinterest